Abivax S.A. (ABVX) - Long-Term Debt to Capital Coefficient
ABIVAX (ABVX) specializes in developing advanced immune-based drugs. The asset's market value trend confirms management's ability to attract investment for final-stage trials while maintaining high data transparency. The business is currently implementing automated molecule screening to reduce primary analysis costs. Revenues rely on government procurement of therapies for intestinal inflammation, with the indicator standing at 0.00.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvujvhid.si-7ayy9s0&start=20220704&end=20261030&filename=GURU_Markets_-_ABVX_-_ABIVAX_-_Long-Term-Debt-to-Capital "ABVX: ABIVAX Long-Term Debt to Capital 02/21/2024 - 10/30/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Abivax S.A. (ABVX)
- stock price and consensus target price:
- market capitalization indicators:
- balance sheet net asset value indicators:
- debt and solvency information:
- net income and valuation ratios data:
General company analysis:ABIVAX - ABVX
The development of the patent portfolio and the battle for biotech leadership at ABIVAX (ABVX) are reflected in the long-term debt financial leverage ratio. The ratio of liabilities with a maturity of more than one year to equity determines the company's degree of dependence on borrowed capital, allowing investors to assess the balance between aggressive infrastructure expansion and the risk of losing financial stability during external shocks.
Key competitors
argenx N.V. - Long-Term Liabilities to Equity|Long-Term Debt to Capital BNTX|ADMA (ADMA Corp) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital PTGX (Protagonist Therapeutics)|Long-Term Debt to Capital immunovant.com IMVT|KNSA - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient GRFS (Grifols SA)|Adaptive Biotechnologies Corp (ADPT) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Celldex Corp|AUPH (Aurinia Pharmaceuticals) - Long-Term Debt to Capital|Long-Term Debt to Capital biocryst.com|Long-Term Debt to Equity Ratio VERA (Vera Therapeutics)|DNTH (Dianthus Therapeutics Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital PHVS (Pharvaris Corp)|Ratio of Long-Term Indebtedness to Capital AbCellera (ABCL)|TRML - Long-Term Debt to Equity|precigen.com (PGEN) - Long-Term Debt to Equity Ratio|Pharming Group (PHAR) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Nektar Therapeutics Inc|Long-Term Debt to Equity Ratio UPB|Long-Term Debt to Capital Zenas Corp|Long-Term Debt to Equity Immunome, Inc. (IMNM)|gossamerbio.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital KALV (KalVista Pharmaceuticals, Inc.)|Septerna, Inc. (SEPN) - Long-Term Liabilities to Capital|Pieris Pharmaceuticals Inc - Long-Term Debt to Capital|SVRA - Long-Term Debt to Capital|RIGL: Long-Term Debt to Capital|ANAB (anaptysbio.com) - Long-Term Debt to Equity|ATXS (Astria Therapeutics, Inc.) - Long-Term Debt to Capital|enGene Holdings Inc (ENGN) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio RAPT (RAPT Therapeutics, Inc.)|Long-Term Debt to Equity JBIO (aerovatetx.com)|Long-Term Debt to Capital ACRS (Aclaris Therapeutics)|Long-Term Debt to Capital kyvernatx.com KYTX|TLSA: Long-Term Debt to Equity Ratio|CABA (Cabaletta Bio Inc.) - Long-Term Debt to Capital Ratio|VTYX: Long-Term Debt to Capital|Theratechnologies, Inc (THTX) - Long-Term Debt to Capital|AVTX (Avalo Therapeutics, Inc) - Long-Term Debt to Capital|Long-Term Debt to Equity ELDN|Long-Term Debt to Equity Ratio AGEN (Agenus Inc.)|Long-Term Debt to Equity CLYM (Climb Bio Inc.)|Zura Bio Limited - Long-Term Debt to Equity Ratio|ATYR: Long-Term Debt to Capital Ratio|ADAG - Long-Term Debt to Equity|Long-Term Liabilities to Equity IMA|STTK: Long-Term Debt to Capital|Equillium - Long-Term Debt to Capital Coefficient|CNTB (Connect Biopharma Holdings) - Long-Term Debt to Capital|Long-Term Debt to Capital Immunic Inc|Long-Term Debt to Equity Atara Biotherapeutics (ATRA)|IFRX (inflarx.de) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity X4 Pharmaceuticals, Inc. XFOR|ACET - Long-Term Debt to Equity Ratio|Celularity Corp - Long-Term Debt to Capital|INMB - Long-Term Debt to Capital|BRNS (Barinthus Biotherapeutics) - Long-Term Debt to Equity Ratio|kezarlifesciences.com - Long-Term Debt to Capital Coefficient|SABS (SAB Biotherapeutics, Inc.) - Long-Term Debt to Capital|Akari Therapeutics PLC (AKTX) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Enlivex Therapeutics (ENLV)|Long-Term Debt to Equity Ratio q32bio.com QTTB|Long-Term Debt to Equity GeoVax Labs, Inc. GOVX|EDSA - Long-Term Debt to Equity Ratio|IBIO: Long-Term Debt to Equity Ratio|CARM - Long-Term Debt to Capital|XTL Biopharmaceuticals, Ltd. (XTLB) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio BOLT|HCWB (HCW Biologics, Inc.) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Aptevo APVO|Long-Term Debt to Capital AIM|Long-Term Debt to Capital aditxt.com (ADTX)|Long-Term Debt to Capital GRI (GRI Bio Corp)|XORTX Corp - Long-Term Debt to Equity|Vyome Holdings Inc - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital revbiosciences.com REVB|INDP (Indaptus Therapeutics, Inc.) - Long-Term Debt to Equity Ratio|SCNI (Scinai Immunotherapeutics Ltd) - Long-Term Debt to Equity|CALI (CalciMedica Inc) - Long-Term Debt to Capital|Long-Term Debt to Capital Affimed Therapeutics|Long-Term Debt to Equity Ratio ALLK (Allakos Inc.)|hookipapharma.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital IGMS (IGM Biosciences)|Long-Term Debt to Capital iTeos Therapeutics Inc ITOS|Ocean Bio - Long-Term Debt to Capital|TCBP: Long-Term Debt to Equity|THRD (Third Harmonic Bio) - Long-Term Debt to Equity Ratio